Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations

Background: Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec®) inhibits several protein tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and c-kit, which are preferentia...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Cristofanilli, M., Morandi, P., Krishnamurthy, S., Reuben, J. M., Lee, B.-N., Francis, D., Booser, D. J., Green, M. C., Arun, B. K., Pusztai, L., Lopez, A., Islam, R., Valero, V., Hortobagyi, G. N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2008
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2735063/
https://ncbi.nlm.nih.gov/pubmed/18515258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn352
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller